Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
| Form | Size | Price | $/mg | Stock | Updated |
|---|---|---|---|---|---|
| vial | 100mg | $75.00 | $0.75/mg | In stock | Jul 27 |
| vial | 200mg | $135.00 | $0.68/mg | In stock | Jul 27 |
| vial | 400mg | $255.00 | $0.64/mg | In stock | Jul 27 |
Single-vial list prices — bulk or bundle orders may be lower. Verify at vendor before purchase.
| Lot / Report | Tested | Purity | Lab | Panels | Status | |
|---|---|---|---|---|---|---|
| 665394 | Apr 2026 | — | Freedom Diagnostics | Endotoxin | Confirmed | View |
In FDA Category 1 for non-injectable routes only (restored May 14, 2026); injectable routes were removed from Category 2 on April 22, 2026 and are not authorized. Category 1 is FDA's “under evaluation” enforcement-discretion policy — not a finding of safety or efficacy, and not the 503A bulks list. Alongside Vasoactive Intestinal Peptide, GHK-Cu is one of only two peptides in Category 1 today.
Does Blank Peptides sell GHK-Cu?
Yes — Blank Peptides currently lists GHK-Cu in 3 variants starting at $255.00 ($0.64/mg).
Is Blank Peptides's GHK-Cu third-party tested?
Yes — Disclosed Labs has indexed 1 Certificate of Analysis for Blank Peptides's GHK-Cu. Blank Peptides holds an overall trust grade of B (80/100) across all 138 COAs on file.
What is Blank Peptides's trust grade for GHK-Cu?
Blank Peptides has an overall Disclosed Labs trust grade of B (80/100), computed from 138 COAs across all peptides. The most recent GHK-Cu COA was issued by Freedom Diagnostics.
Where is the cheapest GHK-Cu?
As of the latest data, Peptide Supply Co. offers GHK-Cu at $0.28/mg — compare with Blank Peptides's listing at $0.64/mg. See the full GHK-Cu price comparison.
What is the FDA compounding status of GHK-Cu?
In FDA Category 1 for non-injectable routes only (restored May 14, 2026); injectable routes were removed from Category 2 on April 22, 2026 and are not authorized. Category 1 is FDA's “under evaluation” enforcement-discretion policy — not a finding of safety or efficacy, and not the 503A bulks list. Alongside Vasoactive Intestinal Peptide, GHK-Cu is one of only two peptides in Category 1 today. Sales tracked here are for research purposes only. Disclosed Labs does not provide medical or legal advice.
Disclosed Labs